WSJ cites Novartis setback as warning for pharma M&A
TradingView/WSJ says Novartis’ latest trial setback is being framed as a cautionary tale for investors betting on big pharma’s strategy of bite-size acquisitions to support drug pipelines.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.